Advanced in Venous Thromboembolism (VTE)

Dr. Daniel J. George

Urology | Hematology | Oncology
Duke Health
Duke Health Integrated Practice Inc
2351 Erwin Rd, 
Durham, NC 
Accepting New Patients
Offers Telehealth
Advanced in Venous Thromboembolism (VTE)
Duke Health
Duke Health Integrated Practice Inc
2351 Erwin Rd, 
Durham, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Daniel George is a Urologist and a Hematologist in Durham, North Carolina. Dr. George is rated as an Advanced provider by MediFind in the treatment of Venous Thromboembolism (VTE). His top areas of expertise are Prostate Cancer, Renal Cell Carcinoma (RCC), Familial Prostate Cancer, Nephrectomy, and Orchiectomy. Dr. George is currently accepting new patients.

His clinical research consists of co-authoring 324 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 4 articles in the study of Venous Thromboembolism (VTE).

Specialties
Urology
Hematology
Oncology
Licenses
Urology in NC
Hospital Affiliations
Duke University Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Piedmont
  • HMO
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

DUKE HEALTH INTEGRATED PRACTICE INC
2351 Erwin Rd, Durham, NC 27705
Call: 919-684-8111
Other Locations
DUKE HEALTH INTEGRATED PRACTICE INC
6301 Herndon Rd, Durham, NC 27713
Call: 919-684-8111
DUKE HEALTH INTEGRATED PRACTICE INC
1234 Huffman Mill Rd, Burlington, NC 27215
Call: 919-684-8111
DUKE HEALTH INTEGRATED PRACTICE INC
40 Duke Medicine Cir, Durham, NC 27710
Call: 919-684-8111
DUKE HEALTH INTEGRATED PRACTICE INC
2301 Erwin Rd, Durham, NC 27705
Call: 919-684-8111

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2026
Intervention Type: Drug
Study Drugs: 177Lu-PSMA-617, Androgen Receptor Directed Therapy, Androgen Deprivation Therapy
Study Phase: Phase 3
PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of Androgen Receptor-Directed Therapy in the Treatment of Taxane Naïve Men With Progressive Metastatic Castrate Resistant Prostate Cancer
PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of Androgen Receptor-Directed Therapy in the Treatment of Taxane Naïve Men With Progressive Metastatic Castrate Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2026
Intervention Type: Drug
Study Drug: ARDT
Study Phase: Phase 3
Prospective Study of Apalutamide and Abiraterone Acetate iN ChemoTHerapy-Naïve mEn With mCRPC Stratified by Race
Prospective Study of Apalutamide and Abiraterone Acetate iN ChemoTHerapy-Naïve mEn With mCRPC Stratified by Race
Enrollment Status: Completed
Publish Date: September 12, 2025
Intervention Type: Drug
Study Drugs: ARN-509, Abiraterone Acetate, Prednisone
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Enrollment Status: Completed
Publish Date: March 20, 2023
Intervention Type: Drug
Study Drugs: CB-839, Cabozantinib
Study Phase: Phase 2
A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Seviteronel in Subjects With Castration-Resistant Prostate Cancer
A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Seviteronel in Subjects With Castration-Resistant Prostate Cancer
Enrollment Status: Completed
Publish Date: February 01, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Phase l/ll, Open Label, Dose-escalation Study of Varlilumab (CDX-1127) in Combination With Atezolizumab (MPDL3280A, Anti-PD-L1) in Patients With Advanced Cancer
A Phase l/ll, Open Label, Dose-escalation Study of Varlilumab (CDX-1127) in Combination With Atezolizumab (MPDL3280A, Anti-PD-L1) in Patients With Advanced Cancer
Enrollment Status: Terminated
Publish Date: April 30, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 5 Less Clinical Trials

323 Total Publications

What we can learn from a national tumor pathology registry.
What we can learn from a national tumor pathology registry.
Journal: Cancer
Published: December 15, 2025
View All 323 Publications
Similar Doctors
Elite in Venous Thromboembolism (VTE)
Dr. Thomas L. Ortel
Hematology
Elite in Venous Thromboembolism (VTE)
Dr. Thomas L. Ortel
Hematology

Duke Health Integrated Practice Inc

40 Duke Medicine Cir, 
Durham, NC 
 (0.3 miles away)
919-684-8111
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Thomas Ortel is a Hematologist in Durham, North Carolina. Dr. Ortel is rated as a Distinguished provider by MediFind in the treatment of Venous Thromboembolism (VTE). His top areas of expertise are Venous Thromboembolism (VTE), Antiphospholipid Syndrome, Thrombocytopenia, Deep Vein Thrombosis, and Thalamotomy. Dr. Ortel is currently accepting new patients.

Elite in Venous Thromboembolism (VTE)
Dr. Stephan Moll
Hematology Oncology | Hematology | Oncology
Elite in Venous Thromboembolism (VTE)
Dr. Stephan Moll
Hematology Oncology | Hematology | Oncology

University Of North Carolina At Chapel Hill

101 Manning Dr, 
Chapel Hill, NC 
 (9.6 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Stephan Moll is a Hematologist Oncology specialist and a Hematologist in Chapel Hill, North Carolina. Dr. Moll is rated as a Distinguished provider by MediFind in the treatment of Venous Thromboembolism (VTE). His top areas of expertise are Venous Thromboembolism (VTE), Shwartzman Phenomenon, Deep Vein Thrombosis, Splenectomy, and Bone Marrow Aspiration. Dr. Moll is currently accepting new patients.

Distinguished in Venous Thromboembolism (VTE)
Dr. Nigel S. Key
Hematology Oncology | Hematology
Distinguished in Venous Thromboembolism (VTE)
Dr. Nigel S. Key
Hematology Oncology | Hematology

University Of North Carolina At Chapel Hill

101 Manning Dr, 
Chapel Hill, NC 
 (9.6 miles away)
Languages Spoken:
English, French
See accepted insurances
Accepting New Patients

Nigel Key is a Hematologist Oncology specialist and a Hematologist in Chapel Hill, North Carolina. Dr. Key is rated as an Elite provider by MediFind in the treatment of Venous Thromboembolism (VTE). His top areas of expertise are Hemophilia B, Hemophilia A, Blood Clots, and Sickle Cell Disease. Dr. Key is currently accepting new patients.

VIEW MORE VENOUS THROMBOEMBOLISM (VTE) DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. George's expertise for a condition
ConditionClose
  • Elite
  • Familial Prostate Cancer
    Dr. George is
    Elite
    . Learn about Familial Prostate Cancer.
    See more Familial Prostate Cancer experts
  • Prostate Cancer
    Dr. George is
    Elite
    . Learn about Prostate Cancer.
    See more Prostate Cancer experts
  • Renal Cell Carcinoma (RCC)
    Dr. George is
    Elite
    . Learn about Renal Cell Carcinoma (RCC).
    See more Renal Cell Carcinoma (RCC) experts
  • Distinguished
  • Adult Soft Tissue Sarcoma
    Dr. George is
    Distinguished
    . Learn about Adult Soft Tissue Sarcoma.
    See more Adult Soft Tissue Sarcoma experts
  • Chromophobe Renal Cell Carcinoma
    Dr. George is
    Distinguished
    . Learn about Chromophobe Renal Cell Carcinoma.
    See more Chromophobe Renal Cell Carcinoma experts
  • Clear Cell Sarcoma
    Dr. George is
    Distinguished
    . Learn about Clear Cell Sarcoma.
    See more Clear Cell Sarcoma experts
  • Familial Wilms Tumor 2
    Dr. George is
    Distinguished
    . Learn about Familial Wilms Tumor 2.
    See more Familial Wilms Tumor 2 experts
  • Muscle Invasive Bladder Cancer
    Dr. George is
    Distinguished
    . Learn about Muscle Invasive Bladder Cancer.
    See more Muscle Invasive Bladder Cancer experts
  • Wilms Tumor
    Dr. George is
    Distinguished
    . Learn about Wilms Tumor.
    See more Wilms Tumor experts
View All 7 Distinguished Conditions
  • Advanced
  • Bladder Cancer
    Dr. George is
    Advanced
    . Learn about Bladder Cancer.
    See more Bladder Cancer experts
  • Bone Tumor
    Dr. George is
    Advanced
    . Learn about Bone Tumor.
    See more Bone Tumor experts
  • Nephrectomy
    Dr. George is
    Advanced
    . Learn about Nephrectomy.
    See more Nephrectomy experts
  • Non-Muscle Invasive Bladder Cancer
    Dr. George is
    Advanced
    . Learn about Non-Muscle Invasive Bladder Cancer.
    See more Non-Muscle Invasive Bladder Cancer experts
  • Orchiectomy
    Dr. George is
    Advanced
    . Learn about Orchiectomy.
    See more Orchiectomy experts
  • Urothelial Cancer
    Dr. George is
    Advanced
    . Learn about Urothelial Cancer.
    See more Urothelial Cancer experts
View All 7 Advanced Conditions
  • Experienced
  • Agranulocytosis
    Dr. George is
    Experienced
    . Learn about Agranulocytosis.
    See more Agranulocytosis experts
  • Brain Tumor
    Dr. George is
    Experienced
    . Learn about Brain Tumor.
    See more Brain Tumor experts
  • Breast Cancer
    Dr. George is
    Experienced
    . Learn about Breast Cancer.
    See more Breast Cancer experts
  • Chronic Familial Neutropenia
    Dr. George is
    Experienced
    . Learn about Chronic Familial Neutropenia.
    See more Chronic Familial Neutropenia experts
  • Inflammatory Breast Cancer
    Dr. George is
    Experienced
    . Learn about Inflammatory Breast Cancer.
    See more Inflammatory Breast Cancer experts
  • Lung Cancer
    Dr. George is
    Experienced
    . Learn about Lung Cancer.
    See more Lung Cancer experts
View All 17 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment

    If you are experiencing a medical emergency, call 9-1-1.

    MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

    Patient Details

    This information is for the patient who will be seen at the appointment.

      Close

      Returning patient? Use your address on file with the provider.

      Insurance Details

      Please provide information of the primary insurance holder as the practice may require this information to schedule.

      Insurance Provider *
      Insurance ProviderClose

      Appointments Details

      Let’s get more information about your appointment.

                0 / 1000
                0 / 1000
                By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.